BCL2L11 and Miyoshi myopathy: Compound 1 exhibited considerable activity against multiple myeloma (MM) cells (IC50 = 1.7 μM for OPM2, 3.0 μM for RPMI 8226, and 6.5 μM for MM.1S cells), and the combination of compound 1 with the proteasome inhibitor bortezomib displayed synergy effects in terms of apoptosis induction in MM cells, which was associated with suppression of anti-apoptotic Bcl-2, Bcl-xL, and Mcl-1 and upregulation of pro-apoptotic NOXA and Bim [33].